According to the Washington Times, "The Justice Department's Criminal Division announced Monday that the Indiana-based company, which manufactures and sells medical devices worldwide, made various improper payments or paid bribes from 2000 to 2008 to health care providers in Argentina, Brazil and China to secure lucrative business with hospitals." "During this time, according to information filed in US District Court in Washington, more than $1.5 million in direct and indirect payments were made. Modern Physician reports, "These payments were then falsely recorded as commissions, royalties, consulting fees or scientific incentives, according to the release."
Tuesday, March 27, 2012
Biomet Busted for Bribery
According to the Washington Times, "The Justice Department's Criminal Division announced Monday that the Indiana-based company, which manufactures and sells medical devices worldwide, made various improper payments or paid bribes from 2000 to 2008 to health care providers in Argentina, Brazil and China to secure lucrative business with hospitals." "During this time, according to information filed in US District Court in Washington, more than $1.5 million in direct and indirect payments were made. Modern Physician reports, "These payments were then falsely recorded as commissions, royalties, consulting fees or scientific incentives, according to the release."
Friday, March 23, 2012
Bloomberg: J & J Marketed Vaginal Mesh Without Approval
According to Bloomberg News writers David Voreacos and Alex Nussbaum, Johnson & Johnson sold a vaginal mesh implant for three years before U.S. regulators approved the device.
J&J’s Ethicon unit introduced the Gynecare Prolift device in March 2005, touting it in an annual report as an “innovative and effective surgical option” for weakened pelvic muscles.
Here is the problem. The U.S.Food and Drug Administration said it learned of the Prolift in 2007, when J&J sought approval for a related product. The FDA cleared both devices in May 2008.
Johnson & Johnson’s unauthorized sales might cost it more to resolve lawsuits over the product.
J&J’s unauthorized sales might cost it more to resolve lawsuits over the product. J&J already has endured recalls of artificial hip implants and over-the-counter drugs. Three J&J units have pleaded guilty in the past two years to bribery or illegal marketing of drugs. A fourth agreed to plead guilty in a marketing case.
This type of conduct again raises questions about the FDA’s approval process, which lets companies introduce products without human testing if the agency decides they’re similar to devices already for sale, or so-called predicates.
An FDA report in July found a fivefold jump in deaths, injuries or malfunctions tied to vaginal mesh for prolapsed organs. In September, an advisory panel urged the FDA to reclassify such mesh as “high-risk” devices needing human testing.
In Atlantic City, patients’ lawyers are seeking to interview more than 70 company witnesses, including Gary Pruden and Sheri S. McCoy, the leader of J&J’s pharmaceutical and consumer products unit. Both Pruden and McCoy previously served as company group chairman and worldwide franchise chairman of Ethicon.
J&J’s Ethicon unit introduced the Gynecare Prolift device in March 2005, touting it in an annual report as an “innovative and effective surgical option” for weakened pelvic muscles.
Here is the problem. The U.S.Food and Drug Administration said it learned of the Prolift in 2007, when J&J sought approval for a related product. The FDA cleared both devices in May 2008.
Johnson & Johnson’s unauthorized sales might cost it more to resolve lawsuits over the product.
J&J’s unauthorized sales might cost it more to resolve lawsuits over the product. J&J already has endured recalls of artificial hip implants and over-the-counter drugs. Three J&J units have pleaded guilty in the past two years to bribery or illegal marketing of drugs. A fourth agreed to plead guilty in a marketing case.
This type of conduct again raises questions about the FDA’s approval process, which lets companies introduce products without human testing if the agency decides they’re similar to devices already for sale, or so-called predicates.
An FDA report in July found a fivefold jump in deaths, injuries or malfunctions tied to vaginal mesh for prolapsed organs. In September, an advisory panel urged the FDA to reclassify such mesh as “high-risk” devices needing human testing.
In Atlantic City, patients’ lawyers are seeking to interview more than 70 company witnesses, including Gary Pruden and Sheri S. McCoy, the leader of J&J’s pharmaceutical and consumer products unit. Both Pruden and McCoy previously served as company group chairman and worldwide franchise chairman of Ethicon.
Consumer Reports: Americans want more oversight of Implanted Medical Products
Less than 1% of of implanted medical products are subjected to the strenuous PMA (pre-market approval) process of the FDA. And the draft legislation put together by the House Energy and Commerce Health Subcommittee would actually allow the approval process to go even faster. The Senate Health, Education, Labor and Pensions Committee's draft bill does provide some additional protections for patients once devices are on the market, but does nothing new to prevent potentially unsafe medical devices from being sold in the first place.
But according to a new poll by our publishing pals Consumer Reports, 82% of Americans believe that preventing safety problems is more important than limiting safety testing in order to prevent delays and encourage innovation.
91% of poll respondents said each implant should be safety tested before being sold even when similar implants were in use.
71% said that a new device should not be allowed to be sold based on its similarity to an existing implant that has a safety problem or has been recalled.
94% indicated that medical device makers should be required to do long-term monitoring of implants if there are safety concerns or problems with a particular device. Existing law gives the FDA only limited authority to require such long-term safety monitoring.
95% said that effective consumer protections for medical implants should include a nationwide system for tracking medical implants so patients can be notified about safety problems or recalls. No such system currently exists in the U.S. even though it was required by Congress' previous reauthorization of the law.
66% indicated a high level of concern about safety decisions or recommendations made by expert committees that included doctors who had current financial relationships with medical device makers.
Industry lobbyists have been pushing lawmakers to weaken current rules designed to prevent such conflicts of interest. The Senate and House discussion drafts remove current caps on the percentage of expert committee members that can be granted waivers if they have a conflict of interest, a provision championed by consumer advocates five years ago.
"Recent problems with metal hip implants and surgical mesh have shown how our current system fails to ensure medical devices are safe and effective," said Lisa Swirsky, senior policy analyst for Consumers Union. "Unfortunately, the House bill weakens current standards to speed up device approvals rather than improving safety oversight. The Senate bill offers some improvements but it should be strengthened to require stricter safety testing of new implants and life sustaining devices. Congress should recognize that the public is far more concerned about making sure devices are safe and work than how quickly they are made available."
The Depuy hip problems came to light, in part, due to tracking systems in place in other countries, which indicated higher than normal failure rates. In this country, the information received by doctors is often limited to data provided by the manufacturer and their sales representatives, which is often times false and misleading.
As one of my clients told me this morning, "I don't need a doctor to tell me that my hip has failed and needs to be removed, I live it every day."
But according to a new poll by our publishing pals Consumer Reports, 82% of Americans believe that preventing safety problems is more important than limiting safety testing in order to prevent delays and encourage innovation.
91% of poll respondents said each implant should be safety tested before being sold even when similar implants were in use.
71% said that a new device should not be allowed to be sold based on its similarity to an existing implant that has a safety problem or has been recalled.
94% indicated that medical device makers should be required to do long-term monitoring of implants if there are safety concerns or problems with a particular device. Existing law gives the FDA only limited authority to require such long-term safety monitoring.
95% said that effective consumer protections for medical implants should include a nationwide system for tracking medical implants so patients can be notified about safety problems or recalls. No such system currently exists in the U.S. even though it was required by Congress' previous reauthorization of the law.
66% indicated a high level of concern about safety decisions or recommendations made by expert committees that included doctors who had current financial relationships with medical device makers.
Industry lobbyists have been pushing lawmakers to weaken current rules designed to prevent such conflicts of interest. The Senate and House discussion drafts remove current caps on the percentage of expert committee members that can be granted waivers if they have a conflict of interest, a provision championed by consumer advocates five years ago.
"Recent problems with metal hip implants and surgical mesh have shown how our current system fails to ensure medical devices are safe and effective," said Lisa Swirsky, senior policy analyst for Consumers Union. "Unfortunately, the House bill weakens current standards to speed up device approvals rather than improving safety oversight. The Senate bill offers some improvements but it should be strengthened to require stricter safety testing of new implants and life sustaining devices. Congress should recognize that the public is far more concerned about making sure devices are safe and work than how quickly they are made available."
The Depuy hip problems came to light, in part, due to tracking systems in place in other countries, which indicated higher than normal failure rates. In this country, the information received by doctors is often limited to data provided by the manufacturer and their sales representatives, which is often times false and misleading.
As one of my clients told me this morning, "I don't need a doctor to tell me that my hip has failed and needs to be removed, I live it every day."
Thursday, March 1, 2012
British Medical Journal---Safety of Metal on Metal Hip Implants Questioned
February 28, 2012
The British Medical Journal reported today that a million or more Americans have had metal on metal orthopedic implants installed since 2003. That number continues to climb as as manufacturers continue to promote metal on metal devices. This, despite the recall of devices (Depuy ASR), growing evidence of exposure to toxic and potentially carcinogenic metal ions, and the unprecedented requirement by the FDA that manufacturers conduct post-marketing studies.
Startling Highlights Contained in the Report Include the Following:
*Failure rates for all metal on metal hip implants is currently 13.6% as opposed to 3.3% for implants made of other materials.
*Multiple studies and research organizations have warned about the carcinogenic potential of metal-on-metal hip implants.
*Internal Depuy memos from July 2005 identify potential immune function changes and carcinogenic concern.
*Because of concerns, Depuy sales representatives were given paper entitled "Setting the record straight on metal hypersensitivity" written by Dr. Thomas Schmalzried (Depuy's hired consultant, stooge, or whatever you want to call him).
*In 2006, based on concerns, the MHRA (Medicines and Healthcare Products Regulatory Agency) committtee concluded that "there is evidence to suggest that some metal-on-metal hip replacements may be associated with increased DNA changes.
*Data showed raised metal ion levels in the Depuy Pinnacle were available since 2008, yet the device was promoted as the alternative for the subsequently recalled Depuy ASR.
*Speaking of the lax regulatory environment, one Depuy product manager responded to an email stating that "you could literally implant a tent rod if you wanted!"
Unfortunately for those with MOM implants, I fear that the news is only going to get worse. The revision rate on our Depuy ASR clients is currently 46% and climbing.
If you have a MOM hip implant, it is imperative that you have regular blood tests for cobalt and chromium.
For additional information, feel free to contact me at Chrish@PittmanDutton.com
Related articles
- Serious concerns over Metal on Metal Hips - British Medical Journal (earlsview.com)
- Metal scare over hip replacement joints (guardian.co.uk)
- Jeremy Laurance: The regulator needs to recover its grip, fast (independent.co.uk)
- Hip implant fiasco highlights regulatory failings in Europe (guardian.co.uk)
- Thouands with metal-on-metal hip implants will need annual checks - WalesOnline (walesonline.co.uk)
- Metal Hip Implant Concerns - Potentially Bigger Scandal Than Breast Implants (medicalnewstoday.com)
Wednesday, February 22, 2012
What did Johnson & Johnson know about their hips and when did they know it?
According to the New York Times, a year before Johnson & Johnson's Depuy division recalled their ASR hip systems, Pamela Plouhar, vice president of Depuy Orthopedics, reported privately to top executives that the FDA was going to refuse to approve the device after data showed it failed prematurely in "significant" numbers. The device was on the market overseas starting in 2003 and was marketed in the United States in 2005 under a loophole in the law.
This, of course, is in direct conflict with public statements by Johnson & Johnson which insisted that its internal studies refuted complaints by surgeons and regulators in other companies. Johnson & Johnson maintained that the failures were the result of improper placement of the implants by physicians--a position I continue to hear parroted by uninformed doctors or physicians still on Johnson & Johnson's gravy train.
There is only one problem with this defense----the data came from clinical studies performed by surgeons hand picked by Depuy and who received royalties and consulting fees associated with it. In other words, Depuy's hand picked surgeons were seeing failures at the same rate as other Depuy surgeons who were using the product.
In addition to this email, documents filed with a Senate committee indicate knowledge of a serious problem in 2008, nearly 2 years before the hips were recalled.
Of course, lost in this discussion were the hundreds, if not thousands of people who are now suffering crippling injuries as Depuy continued to mislead both surgeons and consumers about the condition of its product.
This, of course, is in direct conflict with public statements by Johnson & Johnson which insisted that its internal studies refuted complaints by surgeons and regulators in other companies. Johnson & Johnson maintained that the failures were the result of improper placement of the implants by physicians--a position I continue to hear parroted by uninformed doctors or physicians still on Johnson & Johnson's gravy train.
There is only one problem with this defense----the data came from clinical studies performed by surgeons hand picked by Depuy and who received royalties and consulting fees associated with it. In other words, Depuy's hand picked surgeons were seeing failures at the same rate as other Depuy surgeons who were using the product.
In addition to this email, documents filed with a Senate committee indicate knowledge of a serious problem in 2008, nearly 2 years before the hips were recalled.
Of course, lost in this discussion were the hundreds, if not thousands of people who are now suffering crippling injuries as Depuy continued to mislead both surgeons and consumers about the condition of its product.
Related articles
- Johnson & Johnson CEO resigns after series of missteps (money.cnn.com)
- Flawed DePuy Hip Implant Had Early F.D.A. Notice (nytimes.com)
- Hip Implant the FDA Rejected Was Marketed Abroad - New York Times (nytimes.com)
- Regulator dithering put hundreds of hip patients at risk (smh.com.au)
- J&J DePuy - Hip Implant that U.S. Rejected Was Sold Overseas (earlsview.com)
Friday, December 30, 2011
Navistar Bus Recall
Navistar, the manufacturer responsible for MaxxForce brand diesel engines, school and commercial buses, trucks, personnel carriers and vehicle parts, has recalled multiple school bus models because of safety defects. Navistar is based in Fort Wayne, Indiana, and manufacturers a number of heavy-duty vehicles for everything from construction and farm use to people and cargo conveyance. The BE and CE series buses are built by subsidiary IC Bus.
Navistar plans to initiate a recall for certain models year 2011 and 2012 IC RE school buses manufactured from February 4, 2010 until June 16, 2011 and 2011 and 2012 bus models IC RE made between August 24, 2010 and June 8,2011. The National Highway Traffic Safety Administration (NHTSA) issued a report that these models have a positive battery cable that might rub against the hydraulic cooler reservoir-mounting bracket. This defect could lead to an electrical short, which in some cases could result in a fire. No information was given as to how many buses may be affected by this defect. The New York Times reported that up to 15,500 buses could be affected by this recall.
Navistar also plans to recall approximately 340 buses with model years 2011 and 2012 CE and RE manufactured from October 8, 2009 until April 14, 2011 because they were made without, or with improperly installed, floor channel reinforcements. This means the buses do not conform with seat back rear force displacements requirements and raise the risk of passenger rearward ejection.
In December of 2011, Navistar recalled certain model year 2012 International Durastar and IC Bus HC Heavy trucks and buses manufactured from February 10, 2011, through February 18, 2011, that were equipped with a Meritor MFS08 Series Non-Drive front steer axle. During the assembly process, the steering attachment bolts may have been insufficiently torqued. Insufficient torque of the steering arm bolts may result in bolt fatigue and fracture and/or arm separation, thereby potentially resulting in loss of steering control and increasing the risk of a crash. No injuries were associated with these recalls. Navistar plans to notify owners soon and work with them to repair the buses free of charge.
Our firm is currently investigating claims for those people who have been by a recalled Navistar bus. If you would like a free case evaluation, please contact Booth Samuels at toll free 1-866-515-8880 or at booths@pittmandutton.com.
Wednesday, November 2, 2011
ILLINOIS CONGRESSMAN: NCAA = MAFIA
Source: Fox News
Read more: http://www.foxnews.com/politics/2011/11/01/illinois-congressman-compares-ncaa-to-mafia/#ixzz1cYpC4ILb
Illinois Congressman Bobby Rush said Tuesday "I think you would compare the NCAA to Al Capone and to the Mafia."
Rush made the accusations at the forum called to look at the impact of "back-room deals, payoffs and scandals" in college sports. The congressman spoke after hearing from a couple of mothers of former student-athletes who complained of ill treatment by schools after their sons suffered injuries.One mother, Valerie Hardrick, said the University of Oklahoma refused to grant a waiver for medical hardship that would allow her son, Kyle Hardrick, to play basketball at junior college after transferring from OU. Prior to Tuesday's forum, Hardrick's family provided to The Associated Press documentation showing that team doctors diagnosed him with a torn meniscus in his knee and wrote down on practice logs that he should be held out because he was hurt. Hardrick's family said the university has refused to pursue the waiver unless the family agrees to a settlement that would prohibit him or his family members from enrolling at Oklahoma or any of the universities governed by its board of regents. The proposed settlement also would prevent the Hardricks from filing a lawsuit against the university.
"My insurance does not cover all of Kyle's medical bills," an emotional Valerie Hardrick said. "The University of Oklahoma refused to pay for Kyle's surgery, his rehab, and his medication. The university actions also allowed Kyle to be released without appropriate medical treatment before consulting his original surgeon."
The NCAA requires schools to certify that an athlete has insurance coverage for athletically-related injuries, up to the deductible of the NCAA Catastrophic Injury Insurance Program (currently $90,000). The insurance coverage can be offered by the school, a parent or a personal policy of the athlete.
Two NBA players also participated in the forum, Thaddeus Young of the Philadelphia 76ers and Shane Battier, a free agent who last played with the Memphis Grizzlies.Battier described a college regimen at Duke that included a workout at 6:30 a.m., followed by classes, practice between 4 and 7:30 p.m., and wrapping up schoolwork at 11:30 or midnight.
"It is a full-time job," he said.
Battier called the NCAA's decision last week to allow conferences to provide student-athletes up to $2,000 in spending money "a great start."
"Is that a game-changer? No. What is a game-changer? A game-changer is guaranteeing four-year scholarships. That's a game-changer," Battier said. "A game-changer is, `If you commit to our school, and you graduate, we will pay for any graduate degree that you would like to pursue."'
Ramogi Huma, president of the National College Players Association, called the $2,000 a step in the right direction. But he said it shouldn't be optional, and that it still leaves a shortfall. His group has calculated the average scholarship shortfall for men's basketball and football at the Football Bowl Subdivision level at around $3,200.
Read more: http://www.foxnews.com/politics/2011/11/01/illinois-congressman-compares-ncaa-to-mafia/#ixzz1cYpC4ILb
Subscribe to:
Posts (Atom)

